Straximm Therapeutics is a drug discovery company focused on immuno-oncology and especially the STING pathway. Straximm is developing a multimodal approach to activating the STING pathway to treat cancer. Our multimodal approach employs a combination of engineered viruses and small molecules.
Arun is the Founder and CEO at Straximm Therapeutics. He previously co-founded Aten Porus Lifesciences, Oraxion Therapeutics and Avaliv Therpaeutics, R&D companies focused on drug discovery. Arun was instrumental in the licensing of Oraxion’s technology platform to a US based biotech company for $125 MM. Arun holds an MBA from the Royal Melbourne Institute of Technology (Australia), and a Bachelor of Science degree from Christ University (India). Arun has over 10 years of experience as an entrepreneur in various aspects of business including Finance, Operations, Technology transfer and Business development.
Aditya is the Founder and CSO at Straximm Therapeutics. He previously co-founded Aten Porus Lifesciences, Oraxion Therapeutics and Avaliv Therapeutics, R&D companies focused on drug discovery. Aditya is the inventor of Oraxion’s technology platform that was eventually licensed to a US based biotech company for $125 MM. He has co-authored >15 papers and filed several international patents in the areas of nucleic acid delivery, Niemann-Pick Type C therapeutics, and drug discovery. He has been a recipient of scholarships during his Masters and PhD and was also awarded the H. C. Brown Award for Outstanding Organic Research at Purdue University in June 2012. Aditya has a PhD in Bioorganic Chemistry from Purdue University (USA), MS in Chemical Biology from Leeds University (UK), and B.Sc in Chemistry from Christ University (India).
Rohan is the Founder and Director at Straximm Therapeutics. He previously co-founded Viravecs Labs, a biotech startup providing services in genome editing, cell line development, animal model development, transfections, etc. to academics, pharma and biotech companies in India. Rohan has extensive experience in genome engineering techniques, virus production and engineering, etc. His work at Straximm focuses on engineering of viruses as vectors for cancer gene therapy, evaluation of these systems in cell and animal models and evaluation of novel small molecule cancer immunotherapeutics in cell and animal models. Rohan completed his PhD in Applied Biology at ACTREC (Mumbai), followed by Postdoctoral Research at NCBS. Upon completion of his postdoctoral research, he was a research associate at InStem before founding Viravecs Labs.
Srinivasan is the Founder and Director at Straximm Therapeutics. He previously co-founded Aten Porus Lifesciences an Oraxion Therapeutics, both R&D companies focusesd on drug discovery. He is currently serving as the CEO of Porus Labs, a chemical manufacturing conglomerate serving customers across India, US, and Europe. Srinivasan has over 10 years of experience in varied aspects of business including technology transfer, SCM, Business Development and Finance. Srinivasan has an MS in Pharmaceutics from Northeastern University (USA), and B.Pharm from BITS Pilani (India).
Tom serves as the CBO at Straximm Therapeutics. Tom was also CBO at Oraxion Therapeutics and instrumental in the licensing of its technology platform to a US based biotech company for $125 MM. He previously served as the CEO of Mucosis, a leading vaccine development company, having joined from Novavax (NASDAQ) where as Vice President of Strategy he developed and executed a regional partnership strategy with deals in India, Mexico, and South Korea. Prior to Novavax, Tom has previously served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Tom holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University (USA).
STING plays an important role in innate immunity and induces type I interferon production when cells are infected with intracellular pathogens, such as viruses, mycobacteria and intracellular parasites. The activation of Type I Interferons & cytokines further recruits T cells, dendritic cells, macrophages and NK cells that leads to destruction of the infected cells.
Straximm’s approach for the activation of the STING pathway involves a combination of engineered viruses and small molecules for sustained induction of an anti-tumour immune response.
Feel free to email us if you are interested in the project and you want to know more, or to just say hello !